| GTO ID | GTC2590 |
| Trial ID | NCT04745403 |
| Disease | Hepatocellular Carcinoma |
| Altered gene | HBV gene |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | HBV TCR-T cells |
| HLA | HLA-A*02:01|HLA-A*24:02 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Safety and Tolerability Study of Redirected HBV-Specific T Cells in Patients With Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (SAFE-T-HBV) |
| Year | 2021 |
| Country | Singapore |
| Company sponsor | Lion TCR Pte. Ltd. |
| Other ID(s) | LTCR-HCC-3-3 |
| Cohort 1 | |||||||||||
|
|||||||||||